![Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling | Cell Communication and Signaling | Full Text Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling | Cell Communication and Signaling | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12964-018-0317-z/MediaObjects/12964_2018_317_Fig5_HTML.png)
Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling | Cell Communication and Signaling | Full Text
![Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis - ScienceDirect Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497120381441-gr1.jpg)
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis - ScienceDirect
![Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.leu.2403157/MediaObjects/41375_2003_Article_BF2403157_Fig6_HTML.gif)
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia
![Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsj.leu.2403157/MediaObjects/41375_2003_Article_BF2403157_Fig2_HTML.gif)
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C | Leukemia
![P Langen's research works | Max-Delbrück-Centrum für Molekulare Medizin, Berlin (MDC) and other places P Langen's research works | Max-Delbrück-Centrum für Molekulare Medizin, Berlin (MDC) and other places](https://www.researchgate.net/publication/13760486/figure/fig3/AS:981675488051206@1611061083702/Superimposed-original-traces-of-the-increase-in-Ca-2-i-induced-by-ara-C-and-ara-C_Q320.jpg)
P Langen's research works | Max-Delbrück-Centrum für Molekulare Medizin, Berlin (MDC) and other places
![PDF) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG PDF) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG](https://i1.rgstatic.net/publication/26800052_High_dose_ara-C_in_the_treatment_of_newly_diagnosed_acute_promyelocytic_leukemia_Long-term_results_of_the_German_AMLCG/links/00b7d53b3bb957411c000000/largepreview.png)
PDF) High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: Long-term results of the German AMLCG
![Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) | springermedizin.de Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) | springermedizin.de](https://media.springernature.com/lw400/springer-static/cover/journal/277/79/1.jpg?as=jpg)
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML) | springermedizin.de
![PDF) Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of PDF) Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of](https://i1.rgstatic.net/publication/7611563_Low-dose_cytosine_arabinoside_LD-AraC_vs_LD-AraC_plus_granulocyte_macrophage_colony_stimulating_factor_vs_LD-AraC_plus_Interleukin-3_for_myelodysplastic_syndrome_patients_with_a_high_risk_of_developin/links/00b495346fa25f2c4d000000/largepreview.png)
PDF) Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of
![1-β-d-Arabinofuranosylcytosine-5′-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C - Journal of Lipid Research 1-β-d-Arabinofuranosylcytosine-5′-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C - Journal of Lipid Research](https://www.jlr.org/cms/asset/ee1bbe0d-546c-4e63-917c-0b933ac7dd97/gr1.jpg)
1-β-d-Arabinofuranosylcytosine-5′-alkylphosphonophosphates and diphosphates: new orally active derivatives of ara-C - Journal of Lipid Research
![P Langen's research works | Max-Delbrück-Centrum für Molekulare Medizin, Berlin (MDC) and other places P Langen's research works | Max-Delbrück-Centrum für Molekulare Medizin, Berlin (MDC) and other places](https://www.researchgate.net/publication/13760486/figure/fig2/AS:981675488059392@1611061083670/Dose-dependent-growth-inhibition-induced-by-ara-C-and-ara-C-phospholipid-conjugates-1-4_Q320.jpg)
P Langen's research works | Max-Delbrück-Centrum für Molekulare Medizin, Berlin (MDC) and other places
![Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study - The Lancet Oncology Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2113983476/2084460128/gr1.gif)